Association Between TCF21 Gene Polymorphism with the Incidence of Paroxysmal Atrial Fibrillation and the Efficacy of Radiofrequency Ablation for Patients with Paroxysmal Atrial Fibrillation

Xianlin Zhang¹, Juan Huang², Jinlong Li¹, Qiao Lu¹, Yuli Huang¹, Dongyu Lu¹, Yang Tang¹, Jian Zhu¹, Jianhui Zhuang³

¹Department of Cardiology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233004, People’s Republic of China; ²Health Management Centre, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233004, People’s Republic of China; ³Department of Cardiology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, 200072, People’s Republic of China

Correspondence: Jianhui Zhuang, Department of Cardiology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, 200072, People’s Republic of China, Tel +86-13621742833, Email jh_zhuang@tongji.edu.cn

Purpose: Atrial fibrillation (AF) is the most common sustained arrhythmia with a high rate of recurrence after catheter ablation. The gene encoding transcription factor 21 (TCF21) has been linked to coronary artery disease risk by human genome-wide association studies in multiple racial ethnic groups. However, the association of TCF21 with AF remains unclear.

Patients and Methods: Circulating leukocytes in patients with paroxysmal AF (PAF) and 92 age-matched controls without a history of cardiovascular disease, AF and other arrhythmias were collected. A total of 224 PAF patients receiving radiofrequency ablation had an 18-month scheduled follow-up study for recurrence of AF. Three single-nucleotide polymorphisms (SNPs) of TCF21 (rs2327429, rs2327433 and rs12190287) were genotyped by PCR, and serum levels of TCF21 were measured by ELISA.

Results: More males and smokers were observed in the PAF group compared with controls. C allele of rs2327429, G allele and GG genotype of rs12190287 were markedly associated with the increased onset of PAF. The levels of serum TCF21 were significantly higher in PAF group than those in control group (1.96 ± 0.85 vs 0.86 ± 0.49 ng/mL, P<0.001). Based on logistic regression analysis, we confirmed that risk allele at rs12190287 and serum TCF21 concentration were independently correlated with the incidence of PAF. Furthermore, GG genotype of rs12190287 enhanced the susceptibility of AF recurrence after ablation.

Conclusion: G allele and GG genotype of rs12190287 in TCF21 and elevated TCF21 concentration are significantly associated with the onset of PAF and recurrence after ablation.

Keywords: transcription factor 21, paroxysmal atrial fibrillation, single-nucleotide polymorphism, radiofrequency ablation

Introduction

Atrial fibrillation (AF) is the most common human arrhythmia, which affects approximately 3% of adults.¹ Two of its prevalence increases with age and currently become one of the most global health burdens in the elderly population.² Three AF presence affects patient’s quality of life and increases the risk of stroke and heart failure.² Five AF was regarded as a progressive disease and categorized as paroxysmal, persistent and permanent AF. More than 33% of the patients with paroxysmal AF (PAF) develop to persistent AF within 10 years.² Apart from electrical remodeling, atrial fibrosis and structural remodeling are considered to be associated with the initiation and maintenance of AF.⁶ Since trigger from pulmonary veins is a common trigger of AF, pulmonary vein isolation with radiofrequency ablation (RFA) is the mainstay of AF control, especially for drug-refractory PAF patients.⁷ However, a meta-analysis reported that only 30% to 85% patients could successfully maintain sinus rhythm after RFA with a median of 12 months.⁸ Hence, there is an urgent need for a better understanding of the pathogenesis of AF.
Numerous studies demonstrated that AF has a substantial genetic basis.\(^9,10\) Despite risk factors including sex, aging, smoking and comorbidities contribute to the AF risk, a family history of AF also confers a high AF risk.\(^3\) Population-based genome-wide association studies (GWAS) among familial studies shed light on the genetic mutations and polymorphisms associated with AF, such as \(KCNQ1, SCN5A, GATA4\), etc.\(^11\) Nevertheless, more novel biomarkers are still needed for the risk stratification of AF recurrence, which enables better patient’s selection for RFA and post-intervention monitoring.

Transcription factor 21 (TCF21) is a member of the basic helix-loop-helix transcription factor family, and plays a vital role in cell fate and differentiation.\(^12\) In murine models, \(Tcf21\) is required for phenotypic modulation of smooth muscle cells in atherosclerotic tissues and promotes a fibroblast phenotype in these cells.\(^13\) Likewise, TCF21 is essential for the formation of resident cardiac fibroblasts. Mice deficient in \(Tcf21\) failed to produce cardiac fibroblasts and suppress cardiac repair.\(^14\) Human GWAS indicated that single nucleotide polymorphism (SNP) \(rs12190287\) located in the 3’ untranslated region (3’-UTR) of TCF21 was associated with coronary artery disease risk in multiple racial ethnic groups.\(^15–17\) Furthermore, TCF21 \(rs12190287\) polymorphisms also conferred predisposition to ventricular septal defects in a Chinese population.\(^18\) Genetic variants could contribute to the AF pathology by affecting the expression and function of proteins responsible for various cellular activities. Therefore, given the marked effect of TCF21 in cardiovascular diseases, we hypothesized that TCF21 may play an important role in the AF pathogenesis. In the present study, we aimed to investigate the association of TCF21 SNPs with AF patients after RFA in a Chinese population.

**Materials and Methods**

**Study Design**

This study was an observational study of 224 PAF patients and 92 age-matched controls from our institution. Patients over 18 years of age with documented symptomatic PAF were eligible for enrollments if they were refractory to at least one class I to IV antiarrhythmic drug. PAF was defined as AF that terminated spontaneously or with intervention within 7 days of onset according to the diagnostic criteria of guidelines.\(^19\) The mean duration of PAF before ablation was 9.32 months. All patients were administrated with warfarin or new oral anticoagulants for at least 1 month before RFA. Transesophageal echocardiography was performed within 48 hours before operation to exclude left atrial thrombus. Exclusion criteria included 1) malignant tumor; 2) severe liver dysfunction defined by an increase in alanine aminotransferase (ALT) levels 5 times the upper limit of normal;\(^20\) 3) severe renal dysfunction defined by estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m\(^2\); 4) hematologic disorders including leukemia, lymphoma, myelodysplastic syndrome and severe anemia (hemoglobin <60 g/L), and history of cerebral infarction or ischemia within 6 months; 5) myocarditis or cardiomyopathies or heart failure; 6) reversible AF caused by cardiopulmonary surgery, cardiac surgery; 7) left atria diameter (LAD) >60mm. The control subjects without a history of cardiovascular diseases, including coronary artery disease, valvular disease, cardiomyopathy and congenital heart disease, were recruited. Of note, the controls were documented with normal electrocardiogram and had no history of AF or any other cardiac arrhythmias.

RFA performed by well-experienced cardiologists. Briefly, the electrical isolation of the circumferential pulmonary vein lesions was conducted under the guidance of CARTO system (Biosense Webster, USA). Additional ablation lines of the left atrium roof were implemented in less than 5% patients as necessary. The endpoint of RFA was the absence or dissociation of potentials between the pulmonary vein and left atrium.\(^21\)

This study was approved by the Ethics Committee of the First Affiliated Hospital of Bengbu Medical College and complied with the Declaration of Helsinki. Written informed consent was obtained from each subject.

**Social and Clinical Parameters**

Social information was obtained from the subjects, including sex, age, smoking habits, history of diabetes and hypertension. The P wave duration and PR intervals from electrocardiograms under sinus rhythm were collected in all enrollments. The LAD, left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD) and left ventricular ejection fraction (EF) were measured by transthoracic ultrasonic testing. Venous blood samples were
obtained in subjects after overnight fast. Plasma creatinine were assayed by standard methods in the Department of Laboratory Medicine of the First Affiliated Hospital of Bengbu Medical College.

SNPs Selection and DNA Genotyping
All peripheral blood samples were taken in the morning with patients fasting from midnight onward before RFA. According to linkage disequilibrium via Haploview and previous studies, we selected three reported SNPs in TCF21 (rs2327429 T>C, rs2327433 A>G and rs12190287 C>G). Circulating leukocytes in patients with 224 PAF patients and 92 controls were collected for DNA extraction by phenol chloroform. We performed genotyping with the selected SNPs in the samples with TaqMan allelic discrimination via ABI 7900HT (Applied Biosystems, Foster City, CA, USA). The TaqMan assay kits and probes were obtained from Applied Biosystems. All data were analyzed via ABI Prism SDS software version 2.3.

Measurement of Serum TCF21
The serum levels of TCF21 were measured by enzyme-linked immunosorbent assay (ELISA) using commercially available reagent (catalog XPEH1455, Xpressbio, USA), according to the manufacturer’s instruction.

Follow-Up Study
All participants were monitored with ECGs and holter by qualified physicians during hospital stay. AF patients underwent RFA procedure were followed up with clinic visits every 2–3 months for 18 months, or earlier if symptoms were consistent. And, 24-hour holter and 12-lead ECG were preformed to determine the recurrence of AF, defined as any recording of AF on 12-lead ECG or an episode >30 seconds on 24-hour holter after 3-month post-ablation blanking period.

Statistical Analysis
Data were expressed as mean ± standard deviation or numbers with the percentage in parentheses. Differences between PAF patients and control subjects were analyzed by the Student’s t-test and chi-squared test, respectively. Multivariate logistic regressions were conducted to detect the independent determinants of PAF onset and recurrence. AF-free survival in PAF patients among different genotypes were analyzed by Log rank test. SPSS19.0 software was used for statistical analysis. P<0.05 was considered statistically significant.

Results
Characteristics of the Study Participants
Clinical characteristics of participants are presented in Table 1. All PAF patients received RFA therapy. Compared with control subjects, PAF patients had more male (73.2% vs 44.6%, P < 0.01) and more smokers (29.9% vs 16.3%, P = 0.01). There were no significant differences in other factors between PAF patients and control subjects, such as age, diabetes, hypertension, LAD, LVESD, LVEDD, EF and plasma creatinine (all P > 0.05).

Rs12190287 and Serum Concentration of TCF21 Associated with the Risk of PAF Onset
Based on previous findings, we selected three TCF21 polymorphisms (rs2327429, rs2327433, rs12190287) reported to be associated with the incidence of human diseases in Chinese population and investigated these SNPs in our studies. Table 2 shows genotype and allele frequencies of the selected 3 SNPs in TCF21 and serum concentration of TCF21 in PAF patients and control subjects. Rs2327429 (CC genotype and C allele) and rs12190287 (CG/GG genotype and G allele) had different frequencies between PAF patients and control subjects (rs2327429 CC vs TT, P = 0.031; C vs T allele, P = 0.032; rs12190287 CG vs CC, P = 0.020; GG vs CC, P = 0.030; G vs C allele, P = 0.005). We also found that rs12190287 genotype had similar frequencies between female and male groups (P = 0.622). Furthermore,
the levels of serum TCF21 were also significantly higher in the PAF group than those in the control group (1.96 ± 0.85 vs 0.86 ± 0.49 ng/mL, \( P < 0.001 \)). Importantly, only G allele at rs12190287 significantly increased TCF21 serum concentration (\( P < 0.05 \)), but no difference in TCF21 concentration among genotypes of rs2327429 and rs2327433 (\( P = 0.558; P = 0.510 \), respectively) (Figure 1). Moreover, multivariate logistic regression analysis together with conventional risk factors (age, sex, smoking, diabetes and hypertension) validated that the onset of PAF was significantly associated with rs12190287 (adjusted odds ratio 2.732, \( P = 0.036 \)) and serum concentration of TCF21 >1.63 ng/mL (adjusted odds ratio 5.824, \( P < 0.001 \), Table 3).

### Association of rs12190287 Genotype with Electrical and Structural Parameters

To further investigate the association of rs12190287 with electrical and structural parameters, we analyzed these parameters (including P wave duration, PR intervals, LAD, LVESD, LVEDD and EF) in different genotypes at

---

**Table 1** Clinical Characteristics of Individuals with and without Paroxysmal Atrial Fibrillation

|                  | Control (n=92) | PAF (n=224) | \( p \)-value |
|------------------|---------------|-------------|--------------|
| Age, years       | 62.8 ± 13.9   | 64.0 ± 10.5 | 0.41         |
| Male             | 41 (44.6)     | 164 (73.2)  | <0.01        |
| Smoking          | 15 (16.3)     | 67 (29.9)   | 0.01         |
| Diabetes         | 25 (27.2)     | 42 (18.8)   | 0.10         |
| Hypertension     | 56 (60.9)     | 151 (67.4)  | 0.27         |
| LAD, mm          | 40.2 ± 4.9    | 40.8 ± 5.5  | 0.33         |
| LVESD, mm        | 47.9 ± 6.5    | 47.3 ± 5.2  | 0.44         |
| LVEDD, mm        | 31.7 ± 6.8    | 31.0 ± 5.5  | 0.34         |
| EF, %            | 59.8 ± 7.8    | 57.5 ± 10.9 | 0.07         |
| Creatinine, μmol/L | 88.3 ± 42.8  | 78.6 ± 27.0 | 0.21         |

**Note**: Data are expressed as mean ± standard deviation.

**Abbreviations**: EF, ejection fraction; LAD, left atrial diameter; LVESD, left ventricular end-systolic diameter; LVEDD, left ventricular end-diastolic diameter; PAF, paroxysmal atrial fibrillation.

**Table 2** Association of TCF21 Polymorphism and Concentration with the Incidence of Paroxysmal Atrial Fibrillation

|                  | Control (n=92) | PAF (n=224) | \( p \)-value |
|------------------|---------------|-------------|--------------|
| rs2327429 TT     | 31 (33.7)     | 102 (45.5)  |              |
| CT               | 40 (43.5)     | 89 (39.7)   | CT vs TT  0.167 |
| CC               | 21 (22.8)     | 33 (14.7)   | CC vs TT  0.031 |
| Allele T         | 106 (56.4)    | 293 (65.4)  | C vs T  0.032 |
| C                | 82 (43.6)     | 155 (34.6)  |              |
| rs2327433 AA     | 28 (30.4)     | 97 (43.3)   |              |
| AG               | 37 (40.2)     | 67 (29.9)   | AG vs AA  0.028 |
| GG               | 27 (30.4)     | 60 (26.8)   | GG vs AA  0.158 |
| Allele A         | 93 (50.5)     | 261 (58.3)  | G vs A  0.076 |
| G                | 91 (49.5)     | 187 (41.7)  |              |
| rs12190287 CC    | 50 (54.3)     | 84 (37.5)   |              |
| CG               | 28 (30.4)     | 90 (40.2)   | CG vs CC  0.020 |
| GG               | 14 (15.2)     | 50 (22.3)   | GG vs CC  0.030 |
| Allele C         | 128 (69.6)    | 258 (57.6)  | G vs C  0.005 |
| G                | 56 (30.4)     | 190 (42.4)  |              |
| TCF21 (ng/mL)    | 0.86 ± 0.49   | 1.96 ± 0.85 | <0.001       |

**Abbreviations**: PAF, paroxysmal atrial fibrillation; TCF21, transcription factor 21.
rs12190287 and found that there were no significant differences between rs12190287 genotype and cardiac function parameters (all $P > 0.05$, Table 4).

**Rs12190287 and Serum Concentration of TCF21 Associated with PAF Recurrence**

With a follow-up time of 18 months, the total PAF recurrence rate in our study was 19.6%. There was no statistical significance in recurrent rate between female and male PAF patients ($P = 0.546$). Multivariate logistic analysis with adjustment for conventional risk factors demonstrated that GG genotype of rs12190287 significantly enhanced the susceptibility of PAF recurrence after RFA (adjusted odds ratio 1.659, $P = 0.032$, Table 5). Further, Log rank test was performed to investigate the association of PAF recurrence among different genotypes at rs12190287, and results indicated that GG genotype at rs12190287 dramatically reduced the freedom rate of PAF recurrence ($P = 0.023$, Figure 2). Interestingly, we found that serum concentration of TCF21 greatly declined after 18 months of follow-up in non-recurrent group (1.93 ± 0.84 vs 1.51 ± 0.78 ng/mL, $P < 0.001$), while TCF21 levels slightly elevated in recurrent group without statistical significance (2.04 ± 0.91 vs 2.09 ± 0.88 ng/mL, $P = 0.334$).

**Discussion**

In the present study, we first reported that a novel SNP rs12190287 (G allele) in TCF21 and serum TCF21 concentration were independently correlated with the incidence of PAF. Moreover, GG genotype of rs12190287 enhanced the susceptibility of PAF recurrence after RFA during a follow-up time of 18 months.

AF, the most common cardiac arrhythmia in clinical practice, represents a major cause of mortality and morbidity, mainly due to embolic events and heart failure. Since it is a disorganized tachyarrhythmia with irregular atrial activity initiated by ectopic foci from around or inside the pulmonary veins, pulmonary vein isolation with catheter ablation is already widely used in the past few decades and associated with high rates of AF freedom in PAF patients.

**Table 3 Multivariate Regression Analysis of Independent Determinants of PAF**

|                  | Exp(B) | 95% CI       | p-value |
|------------------|--------|--------------|---------|
| Age ($>65$ yrs)  | 0.777  | (0.415, 1.457) | 0.432   |
| Male             | 0.218  | (0.115, 0.412) | <0.001  |
| Smoking          | 2.688  | (1.250, 5.781) | 0.011   |
| Hypertension     | 1.631  | (0.856, 3.109) | 0.137   |
| Diabetes         | 0.541  | (0.266, 1.098) | 0.089   |
| rs2327429        | 0.666  | (0.443, 1.003) | 0.052   |
| rs2327433        | 0.731  | (0.500, 1.070) | 0.107   |
| rs12190287       | 2.732  | (1.863, 3.509) | 0.036   |
| TCF21 (>1.63 ng/mL) | 5.824 | (3.397, 8.703) | <0.001  |

Note: Exp(B): adjusted odds ratio.  
Abbreviations: CI, confidence interval; PAF, paroxysmal atrial fibrillation.
Indeed, a significant recurrence rate was observed after RFA at nearly 30% after first intervention and 20% after two or more interventions.\textsuperscript{25} Accumulating evidence indicated that genetic alterations affected AF incidence and recurrence.\textsuperscript{26} GWAS is widely used to identify common SNPs during the development of AF, such as \textit{rs6666258} of \textit{KCNN3-PMVK}, \textit{rs6817105} of \textit{PITX2} and \textit{rs3903239} of \textit{PRRX1}, etc.\textsuperscript{27,28} Despite there is a limitation on the usefulness of just one SNP as a predictor of AF onset/recurrence, adding it to our already established risk factors could be helpful for a prognostic risk stratification in PAF patients before performing procedures. In our study, for the first time, we found that \textit{rs12190287} of \textit{TCF21} was strongly associated with PAF onset and recurrence.

\begin{table}
  \centering
  \caption{Association of rs12190287 Genotype with Electrical and Structural Parameters}
  \begin{tabular}{|c|c|c|c|}
    \hline
    \multicolumn{4}{|c|}{rs12190287} \\
    \hline
    \multicolumn{2}{|c|}{CC (n=134)} & \multicolumn{2}{|c|}{CG (n=118)} & \multicolumn{2}{|c|}{GG (n=64)} & \multicolumn{2}{|c|}{p-value} \\
    \hline
    P wave duration, s & 0.097 ± 0.019 & 0.096 ± 0.018 & 0.100 ± 0.021 & 0.386 \\
    PR intervals, s & 0.147 ± 0.020 & 0.146 ± 0.019 & 0.150 ± 0.021 & 0.386 \\
    LAD, mm & 41.19 ± 5.70 & 39.94 ± 5.05 & 40.72 ± 5.13 & 0.173 \\
    LVEDD, mm & 47.08 ± 5.59 & 47.84 ± 5.75 & 47.91 ± 5.31 & 0.473 \\
    EF, % & 58.04 ± 10.04 & 57.64 ± 10.63 & 59.58 ± 9.49 & 0.485 \\
    \hline
  \end{tabular}
  \end{table}

\textbf{Table 5 Logistic Analysis of Determinants for PAF Recurrence}

\begin{table}
  \centering
  \caption{Logistic Analysis of Determinants for PAF Recurrence}
  \begin{tabular}{|c|c|c|c|}
    \hline
    \multicolumn{4}{|c|}{} \\
    \hline
    \multicolumn{2}{|c|}{Exp(B)} & \multicolumn{2}{|c|}{95\% CI} & \multicolumn{2}{|c|}{p-value} \\
    \hline
    Age (> 65 years) & 0.637 & (0.304, 1.333) & 0.231 \\
    Male & 1.121 & (0.524, 2.398) & 0.769 \\
    Smoking & 0.489 & (0.220, 1.084) & 0.078 \\
    Hypertension & 1.052 & (0.519, 2.132) & 0.889 \\
    Diabetes & 0.691 & (0.278, 1.716) & 0.426 \\
    rs2327429 & 0.932 & (0.573, 1.514) & 0.775 \\
    rs2327433 & 0.836 & (0.558, 1.254) & 0.387 \\
    rs12190287 & 1.659 & (1.044, 2.637) & 0.032 \\
    TCF21 (>1.63 ng/mL) & 1.510 & (0.760, 3.001) & 0.240 \\
    \hline
  \end{tabular}
  \end{table}

\textbf{Note}: Exp(B): adjusted odds ratio.

\textbf{Abbreviations}: CI, confidence interval; PAF, paroxysmal atrial fibrillation.

Indeed, a significant recurrence rate was observed after RFA at nearly 30% after first intervention and 20% after two or more interventions.\textsuperscript{25} Accumulating evidence indicated that genetic alterations affected AF incidence and recurrence.\textsuperscript{26} GWAS is widely used to identify common SNPs during the development of AF, such as \textit{rs6666258} of \textit{KCNN3-PMVK}, \textit{rs6817105} of \textit{PITX2} and \textit{rs3903239} of \textit{PRRX1}, etc.\textsuperscript{27,28} Despite there is a limitation on the usefulness of just one SNP as a predictor of AF onset/recurrence, adding it to our already established risk factors could be helpful for a prognostic risk stratification in PAF patients before performing procedures. In our study, for the first time, we found that \textit{rs12190287} of \textit{TCF21} was strongly associated with PAF onset and recurrence.

\begin{figure}
  \centering
  \includegraphics[width=\textwidth]{af_images.png}
  \caption{Freedom of atrial fibrillation in patients after radiofrequency ablation. Freedom rate of AF recurrence among different genotypes of \textit{rs12190287} in AF patients receiving radiofrequency ablation was compared by Log rank test (Mantel–Cox).}
\end{figure}
Recently, TCF21 was identified as a tumor suppressor gene in several types of cancer.\textsuperscript{22,29,30} Besides that, TCF21 expression was also strongly associated with SMC phenotypic modulation in diseased human coronary arteries by single-cell analysis.\textsuperscript{15} Nagao et al\textsuperscript{13} revealed that SMC-derived TCF1 suppressed SMC differentiation via inhibition of Myocardin-SRF pathway. On the other hand, TCF21 was essential for the formation of resident cardiac fibroblasts, even deficiency of Tcf21 failing to the production and transition of cardiac fibroblasts in mice.\textsuperscript{14} Moore-Morris et al\textsuperscript{31} found that resident cardiac fibroblasts derived from epicardial population, expressing TCF21, mediated pressure overload-induced cardiac fibrosis. As a consequence, excessive extracellular matrix deposition and cardiac fibrosis exacerbated AF and triggered the recurrence of AF after RFA.\textsuperscript{32} Emerging evidence demonstrated that TCF21 polymorphism plays an important role in cancer,\textsuperscript{22,23} coronary artery diseases\textsuperscript{16,17} and ventricular septal defects.\textsuperscript{18} For instance, the CG and GG genotypes of rs12190287 predict elevated risk of osteosarcoma\textsuperscript{23} and conferred genetic susceptibility to VSDs in a Chinese population.\textsuperscript{18} Herein, we provided the first data on the association between TCF21 polymorphism and PAF onset/recurrence. We extracted DNA from circulating leukocytes of PAF patients and control subjects to analyze TCF21 gene polymorphisms. Subsequently, we investigate whether the three SNP candidates were related to the PAF risk and recurrence. Fortunately, we discovered that rs12190287 G allele was significantly associated with a higher risk of PAF onset and recurrence.

It is well known that SNPs in genes may affect gene expression through different mechanisms depending on their locations. Gao et al\textsuperscript{22} reported that rs12190287 C allele had a lower transcription activity than G allele, possibly owing to miRNA-mediated regulation of gene expression influenced by the functional genetic variants in 3’ UTR region. Consistently, we found that C allele at rs12190287 had a lower serum concentration of TCF21 than G allele, suggesting an important role of rs12190287 in PAF onset and recurrence. Further studies on TCF21 were warranted to elucidate the function of TCF21 rs12190287 during the AF pathogenesis.

The findings of the present study need to be interpreted within its limitations. First and foremost, the distribution of rs12190287 genotype fluctuated in Chinese population among different studies.\textsuperscript{18,22,23} It could be partly explained by the fact that the definition of control group may affect the frequencies of rs12190287 among different studies. Although the controls in our study were free of AF and other arrhythmias, some concomitant diseases in control individuals may be underestimated. Second, the sample size was not large enough and inherent selection bias was unavoidable, because all participants were selected from our hospital in a Chinese population. The findings should be further validated in the future through population-based cohorts in different races. Last, TCF21 polymorphisms might be affected by environmental factors or lifestyle.\textsuperscript{23,33}

**Conclusions**

Taken together, TCF21 rs12190287 polymorphism can regulate TCF21 expression, and the G allele and GG genotype of rs12190287 were associated with PAF onset and recurrence. These findings indicated that TCF21 rs12190287 polymorphism may serve as a potential marker for genetic susceptibility to PAF onset and recurrence after catheter ablation in a Chinese population.

**Abbreviations**

AF, atrial fibrillation; PAF, paroxysmal atrial fibrillation; RFA, radiofrequency ablation; SNP, single-nucleotide polymorphism; TCF21, transcription factor 21.

**Data Sharing Statement**

The raw data could be available upon reasonable request to the corresponding author.

**Ethics Approval and Informed Consent**

This study was conducted in accordance with the declaration of Helsinki. This study was conducted with approval from the Ethics Committee of the First Affiliated Hospital of Bengbu Medical College. A written informed consent was obtained from all participants.
Acknowledgment
We thank all participants enrolled in the study.

Funding
This work was supported by grants from the Natural Science Research Project of Bengbu Medical College (No. 2021byzd097), the Natural Science Research Project of Anhui Educational Committee (No. KJ2019A0401), and the Humanity and Social Science Research Project of Anhui Educational Committee (No. SK2020A0351).

Disclosure
The authors report no conflicts of interest in this work.

References
1. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014;6:213–220. doi:10.2147/CLEP.S47385
2. Margulescu AD, Mont L. Persistent atrial fibrillation vs paroxysmal atrial fibrillation: differences in management. Expert Rev Cardiovasc Ther. 2017;15(8):601–618. doi:10.1080/14779072.2017.1355237
3. Lozano-Velasco E, Franco D, Aranega A, Daimi H. Genetics and epigenetics of atrial fibrillation. Int J Mol Sci. 2020;21(16):5717.
4. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–2375. doi:10.1001/jama.285.18.2370
5. Kirchhof P, Benussi S, Kotecha D; for Group ESCS. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962. doi:10.1093/eurheartj/ehw210
6. Qiu D, Peng L, Ghista DN, Wong KKL. Left atrial remodeling mechanisms associated with atrial fibrillation. Cardiovasc Eng Technol. 2021;12(3):361–372. doi:10.1007/s13239-021-00527-w
7. Calkins H, Kuck KH, Cappato R, et al.; for Heart Rhythm Society Task Force on C and Surgical Ablation of Atrial Fibrillation. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter And Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Association (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm. 2012;9(4):632–696 e21. doi:10.1016/j. hrtmg.2011.12.016
8. Balk EM, Garlitski AC, Alsheikh-Ali AA, Terasawa T, Chung M, Ip S. Predictors of atrial fibrillation recurrence after radiofrequency catheter ablation: a systematic review. J Cardiovasc Electrophysiol. 2010;21(11):1208–1216. doi:10.1111/j.1540-8167.2010.01798.x
9. Arnar DO, Thorvaldsson S, Manolio TA, et al. Familial aggregation of atrial fibrillation in Iceland. Eur Heart J. 2006;27(6):708–712. doi:10.1093/ eurheartj/ehi727
10. Ellinor PT, Yoeger DM, Ruskin JN, MacRae CA. Familial aggregation in lone atrial fibrillation. Hum Genet. 2005;118(2):179–184. doi:10.1007/s00439-005-0034-8
11. Lubitz SA, Yin X, Fontes JD, et al. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA. 2010;304(20):2263–2269. doi:10.1001/jama.2010.1690
12. Massari ME, Murre C. Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol Cell Biol. 2000;20(2):429–440. doi:10.1128/MCB.20.2.429-440.2000
13. Nagao M, Lyu Q, Zhao Q, et al. Coronary disease-associated gene TCF21 inhibits smooth muscle cell differentiation by blocking the myocardin-serum response factor pathway. Circ Res. 2020;126(4):517–529. doi:10.1161/CIRCRESAHA.119.315968
14. Acharya A, Baeck ST, Huang G, et al. The bHLH transcription factor Tcf21 is required for lineage-specific EMT of cardiac fibroblast progenitors. Development. 2012;139(12):2139–2149. doi:10.1242/dev.079970
15. Wirka RC, Wagh D, Paik DT, et al. Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis. Nat Med. 2019;25(8):1280–1289. doi:10.1038/s41591-019-0512-5
16. Zhao Q, Wirka R, Nguyen T, et al. TCF21 and AP-1 interact through epigenetic modifications to regulate coronary artery disease gene expression. Genome Med. 2019;11(1):23. doi:10.1186/s13073-019-0635-9
17. Bastami M, Ghaderian SM, Omran MD, et al. MiRNA-related polymorphisms in miR-146a and TCF21 are associated with increased susceptibility to coronary artery disease in an Iranian population. Genet Test Mol Biomarkers. 2016;20(5):241–248. doi:10.1089/gtmb.2015.0253
18. Yang L, Gao X, Luo H, et al. TCF21 rs12190287 polymorphisms are associated with ventricular septal defects in a Chinese population. Genet Test Mol Biomarkers. 2017;21(5):312–315. doi:10.1089/gtmb.2016.0324
19. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–e151. doi:10.1161/CIR.0000000000000665
20. Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf. 2007;30(4):277–294. doi:10.2165/00002018-200730040-00001
21. Efremidis M, Letsas K, Giannopoulos G, et al. Early pulmonary vein reconnection as a predictor of left atrial ablation outcomes for paroxysmal atrial fibrillation. *Europace*. 2015;17(5):741–746. doi:10.1093/europace/euu216

22. Gao X, Yang J, Wang M, Zhang J. TCF21 genetic polymorphisms and breast cancer risk in Chinese women. *Oncotarget*. 2016;7(34):55757–55764. doi:10.18632/oncotarget.9825

23. Jiang Z, Zhang W, Chen Z, Shao J, Chen L, Wang Z. Transcription Factor 21 (TCF21) rs12190287 polymorphism is associated with osteosarcoma risk and outcomes in East Chinese population. *Med Sci Monit*. 2017;23:3185–3191. doi:10.12659/MSM.905595

24. Cheniti G, Vlachos K, Pambrun T, et al. Atrial fibrillation mechanisms and implications for catheter ablation. *Front Physiol*. 2018;9:1458. doi:10.3389/fphys.2018.01458

25. Carballo D, Noble S, Carballo S, et al. Biomarkers and arrhythmia recurrence following radiofrequency ablation of atrial fibrillation. *J Int Med Res*. 2018;46(12):5183–5194. doi:10.1177/0300060518793807

26. Feghaly J, Zakka P, London B, MacRae CA, Refaat MM. Genetics of atrial fibrillation. *J Am Heart Assoc*. 2018;7(20):e009884. doi:10.1161/JAHA.118.009884

27. Ellinor PT, Lunetta KL, Albert CM, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. *Nat Genet*. 2012;44(6):670–675. doi:10.1038/ng.2261

28. Ihida-Stansbury K, McKean DM, Gebb SA, et al. Paired-related homeobox gene Prx1 is required for pulmonary vascular development. *Circ Res*. 2004;94(11):1507–1514. doi:10.1161/01.RES.0000130656.72424.20

29. Wang J, Gao X, Wang M, Zhang J. Clinicopathological significance and biological role of TCF21 mRNA in breast cancer. *Tumour Biol*. 2015;36(11):8679–8683. doi:10.1007/s13277-015-3476-1

30. Dai Y, Duan H, Duan C, et al. Down-regulation of TCF21 by hypermethylation induces cell proliferation, migration and invasion in colorectal cancer. *Biochem Biophys Res Commun*. 2016;469(3):430–436. doi:10.1016/j.bbrc.2015.09.109

31. Moore-Morris T, Guimaraes-Camboa N, Banerjee I, et al. Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. *J Clin Invest*. 2014;124(7):2921–2934. doi:10.1172/JCI74783

32. Quah JX, Dharmaprani D, Tiver K, et al. Atrial fibrosis and substrate based characterization in atrial fibrillation: time to move forwards. *J Cardiovasc Electrophysiol*. 2021;32(4):1147–1160. doi:10.1111/jce.14987

33. Miller CL, Haas U, Diaz R, et al. Coronary heart disease-associated variation in TCF21 disrupts a miR-224 binding site and miRNA-mediated regulation. *PLoS Genet*. 2014;10(3):e1004263. doi:10.1371/journal.pgen.1004263